These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34491628)

  • 1. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
    Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Mekhemer GAH; Shawky AM; Moustafa MF; Atia MAM
    Mol Inform; 2022 Feb; 41(2):e2060039. PubMed ID: 34491628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
    Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Shawky AM; Mekhemer GAH; Alrumaihi F; Moustafa MF; Atia MAM
    Cell Biochem Biophys; 2021 Jun; 79(2):189-200. PubMed ID: 33954893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study.
    Ibrahim MAA; Abdelrahman AHM; Badr EAA; Almansour NM; Alzahrani OR; Ahmed MN; Soliman MES; Naeem MA; Shawky AM; Sidhom PA; Mekhemer GAH; Atia MAM
    Mol Divers; 2022 Dec; 26(6):3255-3277. PubMed ID: 35224675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function relationships in ABCG2: insights from molecular dynamics simulations and molecular docking studies.
    Ferreira RJ; Bonito CA; Cordeiro MNDS; Ferreira MU; Dos Santos DJVA
    Sci Rep; 2017 Nov; 7(1):15534. PubMed ID: 29138424
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Almansour NM; Abdelrahman AHM; Ismail Fagiree E; Ibrahim MAA
    J Biomol Struct Dyn; 2023; 41(16):7651-7664. PubMed ID: 36120948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).
    Zattoni IF; Kronenberger T; Kita DH; Guanaes LD; Guimarães MM; de Oliveira Prado L; Ziasch M; Vesga LC; Gomes de Moraes Rego F; Picheth G; Gonçalves MB; Noseda MD; Ducatti DRB; Poso A; Robey RW; Ambudkar SV; Moure VR; Gonçalves AG; Valdameri G
    Chem Biol Interact; 2022 Jan; 351():109718. PubMed ID: 34717915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing of new tetrahydro-β-carboline-based ABCG2 inhibitors using 3D-QSAR, molecular docking, and DFT tools.
    Ahmad S; Gupta D; Ahmed T; Islam A
    J Biomol Struct Dyn; 2023; 41(23):14016-14027. PubMed ID: 36752362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an
    Ibrahim MAA; Abdeljawaad KAA; Jaragh-Alhadad LA; Oraby HF; Atia MAM; Alzahrani OR; Mekhemer GAH; Moustafa MF; Shawky AM; Sidhom PA; Abdelrahman AHM
    J Biomol Struct Dyn; 2023; 41(23):13977-13992. PubMed ID: 36883864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
    Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
    Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
    Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
    Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
    Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
    Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
    Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel Plasmodium falciparum PI4KB inhibitors as potential anti-malarial drugs: Homology modeling, molecular docking and molecular dynamics simulations.
    Ibrahim MAA; Abdelrahman AHM; Hassan AMA
    Comput Biol Chem; 2019 Jun; 80():79-89. PubMed ID: 30928871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study.
    Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Jaragh-Alhadad LA; Oraby HF; Elkaeed EB; Mekhemer GAH; Gabr GA; Shawky AM; Sidhom PA; Soliman MES; Moustafa MF; Paré PW; Hegazy MF
    Molecules; 2022 May; 27(10):. PubMed ID: 35630581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of the chromone scaffold through QSAR and docking studies: Identification of potent inhibitors of ABCG2.
    Roussel E; Tran-Nguyen VK; Bouhedjar K; Dems MA; Belaidi A; Matougui B; Peres B; Azioune A; Renaudet O; Falson P; Boumendjel A
    Eur J Med Chem; 2019 Dec; 184():111772. PubMed ID: 31630055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.